NCT06553339View on ClinicalTrials.gov

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2028

Conditions
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Oral HS-10516

Oral HIF-2α inhibitor

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT06553339 - A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors | Biotech Hunter | Biotech Hunter